-
HORIZON PHARMA, INC. et al v. DR. REDDY'S LABORATORIES, INC. et al DC CAFC
- 2:13-cv-00091
- D.N.J.
- Judge: Stanley R. Chesler
+1
- Filed: 01/04/2013
- Closed: 07/21/2017
- Latest Docket Entry: 10/03/2019
- PACER
5
Plaintiffs
2
Defendants
1
Accused
Product
2
Patents-in-Suit
1,660
Days in
Litigation
-
HORIZON PHARMA, INC. et al v. DR. REDDY'S LABORATORIES, INC. et al DC CAFC
- 2:13-cv-00091
- D.N.J.
- Judge: Stanley R. Chesler
+1
- Filed: 01/04/2013
- Closed: 07/21/2017
- Latest Docket Entry: 10/03/2019
- PACER
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
5 |
The pharmaceutical composition of claim 1, wherein said acid inhibitor is a proton pump inhibitor selected from the group consisting of: omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole.
|
Valid
Entry 81 |
15 |
The pharmaceutical composition of any one of claims 1 or 7-14, wherein said acid inhibitor is a proton pump inhibitor.
|
Valid
Entry 81 |
52 |
The method of claim 51, wherein said pain or inflammation is due to either osteoarthritis or rheumatoid arthritis.
|
Valid
Entry 81 |
53 |
The pharmaceutical composition of any one of claims 5-11 wherein said unit dosage form is a multilayer tablet comprising a single core and one or more layers outside of said single core, wherein: i) said NSAID is present in said core; ii) said
view more
|
Valid
Entry 81 |
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A pharmaceutical composition in unit dosage form comprising therapeutically effective amounts of: (a) esomeprazole, wherein at least a portion of said esomeprazole is not surrounded by an enteric coating; and (b) naproxen surrounded by a coating that
view more
|
Valid
Entry 81 |
2 |
The pharmaceutical composition of claim 1, wherein naproxen is present in said unit dosage form in an amount of 200-600 mg.
|
Valid
Entry 81 |
3 |
The pharmaceutical composition of claim 1, wherein esomeprazole is present in said unit dosage form in an amount of from 5 to 100 mg.
|
Valid
Entry 81 |
4 |
The pharmaceutical composition of claim 1, wherein naproxen is present in said unit dosage form in an amount of between 200-600 mg and esomeprazole in an amount of from 5 to 100 mg per unit dosage form.
|
Valid
Entry 81 |
-
Infringement
Dr. Reddy's Lab., Inc.
- 2 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
375 mg naproxen/20 mg esomeprazole magnesium, 500 mg naproxen/20 mg esomeprazole magnesium delayed release tablets | US 6,926,907 B2 |
5, 15, 52, 53
|
Infringement
Entry 81
|
375 mg or 500 mg of naproxen, 20.71 mg esomeprazole magnesium delayed release tablets | US 8,557,285 B2 |
1, 2, 3, 4
|
Infringement
Entry 81
|
Dr. Reddy's Laboratories Ltd.
- 2 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
375 mg naproxen/20 mg esomeprazole magnesium, 500 mg naproxen/20 mg esomeprazole magnesium delayed release tablets | US 6,926,907 B2 |
5, 15, 52, 53
|
Infringement
Entry 81
|
375 mg or 500 mg of naproxen, 20.71 mg esomeprazole magnesium delayed release tablets | US 8,557,285 B2 |
1, 2, 3, 4
|
Infringement
Entry 81
|